Giuseppe Pizzi

Giuseppe Pizzi

Auto-generated profile, based on publicly available information

Giuseppe Pizzi

Division of Interventional Radiology, IFO Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2010 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
LSLidia Strigari
Lidia Strigari
RSRosa Sciuto
Rosa Sciuto
SRSandra Rea
Sandra Rea
LCLivio Carpanese
Livio Carpanese
GPGiuseppe Pizzi
Giuseppe Pizzi
CMCarlo Ludovico Maini
Carlo Ludovico Maini
Radioactive 90Y-selective internal radiation (SIR) sphere therapy is increasingly used for the treatment of nonresectable hepatocellular carcinoma (HCC). However, the maximum delivered dose is limited by severe injury to the nontarget tissue, including liver parenchyma. Our study aimed to implement radiobiologic models for both tumor control probability (TCP) and normal-tissue complication probability (NTCP) to describe more effectively local response and the liver toxicity rate, respectively. Methods: Patients with documented HCC, adequate bone marrow parameters, and regular hepatic and pulmonary function were eligible for the study. Patients who had pulmonary shunt greater than 20% of 99mTc-labeled macroaggregated albumin or any uncorrectable delivery to the gastrointestinal tract, reverse blood flow out of the liver, or complete portal vein thrombosis were excluded. Patients received a planned activity of the 90Y-SIR spheres, determined using the empiric body surface area method. The dose distribution was determined using posttreatment (3-dimensional) activity distribution and Monte Carlo dose voxel kernel calculations, and the mean doses to healthy liver and tumor were calculated for each patient. Response was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) and recommendations of the European Association for the Study of the Liver (EASL). Criteria were used to assess possible liver toxicities. The parameters of TCP and NTCP models were established by direct maximization of the likelihood. Results: Seventy-three patients were treated. With an average dose of 110 Gy to the tumor, complete or partial response was observed in 74% and 55% of patients according to the EASL guideline and RECIST, respectively, and the predicted TCPs were 73% and 55%, respectively. With a median liver dose of 36 Gy (range, 6–78 Gy), the ≥grade 2 (G2), ≥grade 3 (G3), and ≥grade 4 (G4) liver toxicities were observed in 32% (23/73), 21% (15/73), and 11% (8/73) of patients, respectively. The parameters describing the ≥G2 liver toxicity data using the NTCP model were a tolerance dose of the whole organ leading to a 50% complication probability of 52 Gy (95% confidence interval, 44–61 Gy) and a slope of NTCP versus dose of 0.28 (95% confidence interval, 0.18–0.60), assuming n = 1. Conclusion: The radiobiologic approach, based on patient-specific dosimetry, could improve the 90Y-microsphere therapeutic approach of HCC, maintaining an acceptable liver toxicity.

13 July 2010 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
F(For The Italian Society Of Locoregional Therapies In Oncology (Sitilo)
For The Italian Society Of Locoregional Therapies In Oncology (Sitilo)
MCM Cosimelli
M Cosimelli
Rita GolfieriRita Golfieri
Rita Golfieri
PCP P Cagol
P P Cagol
LCL Carpanese
L Carpanese
FIFrancesco Izzo
Francesco Izzo
This multi-centre phase II clinical trial is the first prospective evaluation of radioembolisation of patients with colorectal liver metastases (mCRC) who failed previous oxaliplatin- and irinotecan-based systemic chemotherapy regimens. Eligible patients had adequate hepatic, haemopoietic and renal function, and an absence of major hepatic vascular anomalies and hepato-pulmonary shunting. Gastroduodenal and right gastric arteries were embolised before hepatic arterial administration of yttrium-90 resin microspheres (median activity, 1.7 GBq; range, 0.9–2.2). Of 50 eligible patients, 38 (76%) had received 4 lines of chemotherapy. Most presented with synchronous disease (72%), >4 hepatic metastases (58%), 25–50% replacement of total liver volume (60%) and bilateral spread (70%). Early and intermediate (>48 h) WHO G1–2 adverse events (mostly fever and pain) were observed in 16 and 22% of patients respectively. Two died due to renal failure at 40 days or liver failure at 60 days respectively. By intention-to-treat analysis using Response Evaluation Criteria in Solid Tumours, 1 patient (2%) had a complete response, 11 (22%) partial response, 12 (24%) stable disease, 22 (44%) progressive disease; 4 (8%) were non-evaluable. Median overall survival was 12.6 months (95% CI, 7.0–18.3); 2-year survival was 19.6%. Radioembolisation produced meaningful response and disease stabilisation in patients with advanced, unresectable and chemorefractory mCRC.

1 January 2008 in RadioGraphics
Verified
Journal Article
Closed access
BABassel Atassi
Bassel Atassi
ABAffaan K. Bangash
Affaan K. Bangash
ABAmmar Bahrani
Ammar Bahrani
GPGiuseppi Pizzi
Giuseppi Pizzi
RLRobert J. Lewandowski
Robert J. Lewandowski
RSRiad Salem
Riad Salem
Radioembolization with yttrium 90 (90Y) microspheres represents an emerging transarterial therapy for the treatment of liver malignancies that continues to generate interest in the medical community. The classic indication of treatment response is a reduction in tumor size; however, parenchymal changes (eg, necrosis, lack of enhancement, specific findings at positron emission tomography and functional magnetic resonance imaging) and other benign findings (pleural effusions, perivascular edema, contralateral hypertrophy, ring enhancement, perihepatic fluid, fibrosis) may occur following treatment, requiring proper image interpretation. With classic imaging findings and surrogates (time to progression, duration of response, disease-free interval), response rates range from 20% to 80% in patients treated for hepatocellular carcinoma or metastatic disease to the liver. Complications of 90Y radioembolization include cholecystitis, abscess, and bilomas and should be recognized early in the imaging follow-up of ...

1 October 2013 in Journal of Hepatology
Verified
Journal Article
Closed access
Rita GolfieriRita Golfieri
Rita Golfieri
JBJosè Ignacio Bilbao
Josè Ignacio Bilbao
LCLivio Carpanese
Livio Carpanese
RCRoberto Cianni
Roberto Cianni
DGDaniele Gasparini
Daniele Gasparini
SLSecondo Lastoria
Secondo Lastoria

1 June 2019 in European Urology
Verified
Journal Article
Closed access
GSGiuseppe Simone
Giuseppe Simone
GTGabriele Tuderti
Gabriele Tuderti
Umberto AnceschiUmberto Anceschi
Umberto Anceschi
MFMariaconsiglia Ferriero
Mariaconsiglia Ferriero
Manuela CostantiniManuela Costantini
Manuela Costantini
MGMichele Gallucci
Michele Gallucci

5 August 2016 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
GEGiuseppe Maria Ettorre
Giuseppe Maria Ettorre
GSGiovanni Battista Levi Sandri
Giovanni Battista Levi Sandri
ALAndrea Laurenzi
Andrea Laurenzi
MCMarco Colasanti
Marco Colasanti
RMRoberto Luca Meniconi
Roberto Luca Meniconi
GVGiovanni Vennarecci
Giovanni Vennarecci